Longevity Health Stock (NASDAQ:XAGE)

Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.